印度一家三级保健中心的 COVID-19 疫苗接种初步经验。
The initial experience of COVID-19 vaccination from a tertiary care centre of India.
机构信息
Safdarjung Hospital, New Delhi.
Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi.
出版信息
Monaldi Arch Chest Dis. 2021 Mar 31;91(4). doi: 10.4081/monaldi.2021.1816.
To the Editor Drugs Controller General of India (DCGI) has approved the Bharat biotech vaccine against COVID-19, which is a locally manufactured inactivated vaccine named ''COVAXIN'' in collaboration with the Indian council of medical research (ICMR) on 3rd January 2021 for emergency use along with the "Covishield" Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India... *The Safdarjung COVID-19 Vaccination group: KR Meena (Professor, Paediatrics), U Venkatesh (Assistant Professor, Community Medicine), Pushpa Kumari (Associate Professor, Medicine), Sonal Burman (Specialist, Medicine), Neeraj Kumar Gupta (Professor and Head, Pulmonary Medicine), Nitesh Gupta (Assistant Professor, Pulmonary Medicine), Rohit Kumar (Assistant Professor, Pulmonary Medicine), Swetabh Purohit (Senior resident, Pulmonary Medicine), Arjun Ramaswamy (Senior resident, Pulmonary Medicine).
致编辑 印度药品管理总局（DCGI）于 2021 年 1 月 3 日批准了 Bharat biotech 公司研发的 COVID-19 疫苗，这是一种与印度医学研究理事会（ICMR）合作开发的本地生产的灭活疫苗，名为“COVAXIN”，与本地由印度血清研究所生产的牛津-阿斯利康疫苗“Covishield”一起用于紧急使用...*Safdarjung COVID-19 疫苗接种组：KR Meena（儿科教授）、U Venkatesh（社区医学助理教授）、Pushpa Kumari（医学副教授）、Sonal Burman（医学专家）、Neeraj Kumar Gupta（肺病学教授兼主任）、Nitesh Gupta（肺病学助理教授）、Rohit Kumar（肺病学助理教授）、Swetabh Purohit（肺病学高级住院医师）、Arjun Ramaswamy（肺病学高级住院医师）。
Zotero 插件